Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance (Clinical Infectious Diseases, 2021)

Recent Posts

View all

Featured

From evidence to action: what it takes to speed adoption in health care

8 min read

Saira Ghafur, Julia Murphy and Ryan Callahan

From evidence to action: what it takes to speed adoption in health care

8 min read

Saira Ghafur, Julia Murphy and Ryan Callahan

Together with BluePath Health, we recently brought together a small group of cross-sector health leaders in New York for an intimate dinner salon to tackle a shared challenge: why adoption in healthcare still moves too slowly, even when innovation is strong. The conversation centered on what decision-ready evidence really looks like, and how tools like clinical simulation and data sandboxes can help teams learn faster, reduce risk earlier, and move from evidence to action.

8 min read

Saira Ghafur, Julia Murphy and Ryan Callahan

Accessing Europe's biggest digital health market: DiGA reimbursement in Germany explained

12 min read

Mehul Patel

Accessing Europe's biggest digital health market: DiGA reimbursement in Germany explained

12 min read

Mehul Patel

Germany’s pioneering 'apps on prescription' model offers the most structured entry point into the European digital health and medtech market. With access to 73 million insured lives, the potential for scale is unmatched, but the barrier to entry is high. This guide breaks down the essential steps for securing DiGA reimbursement in Germany, from navigating the BfArM Fast-Track and building the right clinical evidence, to preparing for the major regulatory shifts arriving in 2026.